Results of iStopMM: prevalence of smoldering myeloma in the general population Published 2022-01-25 Download video MP4 360p Download video MP4 720p Recommendations 05:54 Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma Cohort 04:41 Genomic characterization of non-progressor smoldering multiple myeloma 01:54 Cilta-cel vs standard of care in functional high-risk myeloma: findings from CARTITUDE-4 01:23 What are the side effects of immunotherapy? 14:46 Excess Deaths at Night - Obstructive Sleep Apnea Explained Clearly 1:21:29 Sauna Benefits Deep Dive and Optimal Use with Dr. Rhonda Patrick & MedCram 01:57 Rationale behind the watch and wait strategy in smoldering myeloma 04:10 Reigniting Hope to Reclaim Movement 02:16 What is Smoldering Myeloma? 03:57 What is chronic lymphocytic leukaemia? 00:56 How do we define smoldering multiple myeloma? 02:00 Should the Free Light Chain Ratio be used as a Myeloma Defining Event | Heinz Ludwig, MD | EHA 2022 18:46 Approach to the Exam for Parkinson's Disease 01:11 Understanding the risk of progression of smoldering myeloma to provide more personalized therapies 04:45 Orthopaedics in Oxford 07:19 Mayo Clinic Explains Lymphoma 02:37 What Causes Smoldering Myeloma and Who is at High Risk? 03:35 Precision medicine and Oxford, challenges and opportunities - Sir John Bell GBE 05:56 Can ruxolitinib replace hydroxyurea as a frontline therapy for PV? 02:54 The combination of FDG PET plus whole-body MRI for diagnosing multiple myeloma Similar videos 06:54 Prevalence of Smoldering Multiple Myeloma: Results from the iStopMM Study 04:08 Smoldering Multiple Myeloma: The iStopMM Study 05:55 MGUS and Risk of Chronic Kidney Disease: Results of the Population-Based iStopMM Study 04:13 Estimating Selection Bias in Previous MGUS Research-the Importance of Screening Results from iStopMM 05:42 Hypercalcemia in Individuals with MGUS: Results from the iStopMM Study 08:02 Screening for Monoclonal Gammopathy of Undetermined Significance: First Results from iStopMM Study 08:07 MGUS with Multiple Paraproteins: Results from the Population-Based iStopMM Screening Study 02:47 iStopMM analysis results: autoimmune diseases are not associated with MGUS 06:05 High Prevalence of Monoclonal Gammopathy in a Population at Risk: Results of the PROMISE Study 06:00 iStopMM - One Year Update 09:36 Screening for myeloma precursors: iStopMM, PROMISE, and the questions they have raised 04:41 First results of PROMISE: MGUS screening in a high-risk population 01:26 Identifying high-risk smoldering myeloma & minimizing treatment-related toxicity 49:36 Multiple Myeloma Precursor Conditions | Overview | Therapeutic Intervention 05:26 Updates from the iStopMM study 01:44 Is there a clear definition for standard-risk smoldering myeloma? 59:27 IMWG Conference Series: Reporting from ASH 2022 1:00:07 iStopMM Study: The first Large-Scale Myeloma Screening Study | 2023 IMF Patient and Family Seminar More results